Clinical trial

Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have…

NCT00061022 · AstraZeneca, Industry · Completed

Key facts

NCT number NCT00061022
Title Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
Official title SAINT (Stroke - Acute Ischemic - NXY Treatment) A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke
Lead sponsor AstraZeneca, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Cerebral Stroke, Stroke, Acute, Cerebrovascular Stroke, Ischemic Attack, Transient
Intervention type Drug
Interventions NXY-059
Enrollment 3,200
Start date May 1, 2003
Primary completion Sep 1, 2006
Completion Sep 1, 2006
First posted May 21, 2003
Last update posted Nov 15, 2010
Countries Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, France, Germany and 18 more

At a glance

  • 100–999 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies